We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Women in Ireland will soon be able to take advantage of diagnostic testing services provided by Quest Diagnostics Incorporated. Through a contract with the Irish National Cancer Screening Service (NCSS), Quest Diagnostics will provide quality-assured screening services intended to improve medical outcomes and reduce anxiety wait time for women ages 25 to 60 who participate in Ireland's first nationwide cytology-screening program.

"Cervical cancer is a terrible disease that often strikes when a woman is in the prime of her life," said Ronald Kennedy, M.D., Corporate Medical Director, Quality Assurance in Anatomic Pathology, Quest Diagnostics.

"Our goal for this historic cytology-screening program is to ensure that Irish women experience the highest quality of testing and service excellence, with the goal of minimizing the incidence of cervical cancer. Our commitment to women's health, along with our industry leading quality-assurance practices, makes us imminently qualified to deliver the superior testing services that Irish women deserve."

Under the cytology-screening program, Quest Diagnostics will perform testing on approximately 300,000 Pap smears annually at two accredited, full-service laboratories in the U.S.

The company operates approximately 30 accredited full-service laboratories in the U.S. that could provide backup capabilities if required.

In addition, Quest Diagnostics will provide general practitioners and consultant colposcopists in Ireland with a toll-free phone number to consult with Quest Diagnostics' medical experts about a patient's test results.

"We applaud the NCSS for its commitment to developing a nationwide program designed to improve the health of women through regular cervical-cancer screening," said Kenneth R. Finnegan, Vice President, International, Quest Diagnostics. "We look forward to working with the NCSS and the entire medical community of Ireland to deliver world-class diagnostic services that enhance the health of Irish women."